Anti-angiogenic activity of selected receptor tyrosine kinase inhibitors, PD166285 and PD173074: Implications for combination treatment with photodynamic therapy

Investigational New Drugs

Volumn 17, Issue 2, 1999, Pages 121-135

  Dimitroff, Charles J ^a   Klohs, Wayne ^b   Sharma, Amarnath ^c   Pera, Paula ^a   Driscoll, Denise ^b   Veith, Jean ^a   Steinkampf, Randall ^b   Schroeder, Mel ^b   Klutchko, Sylvester ^b   Sumlin, Adam ^d   Henderson, Barbara ^d   Dougherty, Thomas J ^d   Bernacki, Ralph J ^e  

^a HARVARD MEDICAL SCHOOL   (United States)

^b PFIZER INC   (United States)

^c GLAXOSMITHKLINE   (United Kingdom)

^d Department of Photodynamic Therapy ^*

^e ROSWELL PARK CANCER INSTITUTE   (United States)

Author keywords

Angiogenesis; Cytostatic chemotherapy; Tyrosine kinase inhibitors

Indexed keywords

ANGIOGENESIS INHIBITOR; EPIDERMAL GROWTH FACTOR RECEPTOR; FIBROBLAST GROWTH FACTOR RECEPTOR; MATRIGEL; PD 166285; PD 173074; PLATELET DERIVED GROWTH FACTOR RECEPTOR; PROTEIN TYROSINE KINASE; PROTEIN TYROSINE KINASE INHIBITOR; UNCLASSIFIED DRUG;

ANGIOGENESIS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER CELL; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFICACY; DRUG POTENCY; ENZYME INHIBITION; FEMALE; HUMAN; HUMAN CELL; MOUSE; NONHUMAN; ORAL DRUG ADMINISTRATION; PHOTODYNAMIC THERAPY; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; TUMOR BLOOD FLOW; TUMOR GROWTH; UMBILICAL VEIN; VASCULAR ENDOTHELIUM;

ANGIOGENESIS INHIBITORS; ANIMALS; ANTINEOPLASTIC AGENTS; CAPILLARIES; CELL DIVISION; CELL LINE; COMBINED MODALITY THERAPY; DOSE-RESPONSE RELATIONSHIP, DRUG; ENDOTHELIUM, VASCULAR; ENZYME INHIBITORS; FEMALE; HUMANS; HYPERKERATOSIS, EPIDERMOLYTIC; INHIBITORY CONCENTRATION 50; MICE; MICE, INBRED C3H; PHOTOCHEMOTHERAPY; PYRIDONES; PYRIMIDINES; RECEPTOR PROTEIN-TYROSINE KINASES; SKIN; SURAMIN; SURVIVAL RATE; TIME FACTORS; TUMOR CELLS, CULTURED; UMBILICAL VEINS;

EID: 0032761526     PISSN: 01676997     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1006367032156     Document Type: Article

References (61)

1. Tronick SR, Aaronson SA: Growth factors and signal transduction. In: J. Mendelsohn, P. M. Howley, M. A. Israel and L. A. Liotta editors. The Molecular Basis of Cancer. Philadelphia: W.B. Saunders Co.: p. 117-40, 1995
2. Merenmies J, Parada LF, Henkemeyer M: Receptor tyrosine kinase signaling in vascular development. Cell Growth Diff 8: 3-10, 1997
3. Risau W: Mechanisms of angiogenesis. Nature, 386(17): 671-74, 1997
4. Beck L Jr, D'Amore PA: Vascular development: cellular and molecular regulation. FASEB J 11(5): 365-73, 1997
5. Plate K H, Breier G, Weich HA, Risau W: Vascular endothelial growth factor is a potential tumour angiogenesis factor in human gliomas in vivo. Nature 359: 843-45, 1992
6. Fernig DG, Gallagher JT: Fibroblast growth factors and their receptors: an information network controlling tissue growth, morphogenesis and repair. Prog Growth Factor Res 5(4): 353-77, 1997
7. Klagsbrun M, D'Amore PA: Vascular endothelial growth factor and its receptors. Cytokine Growth Factor Rev 7(3): 259-70, 1996
8. Battegay EJ, Rupp J, Iruela-Arispe L, Sage EH, Pech M: PDGF-BB modulates endothelial proliferation and angiogenesis in vitro via PDGF ß-receptors. J Cell Bioll25(4): 917-28, 1994
9. Rohovsky SA, Hirschi KK, D'Amore PA: Growth factor effects on a model of vessel formation. Surg Forum 47: 390-91, 1996
10. Panek RL, Lu GH, Klutchko SR, Batley BL, Dahring TK, Hamby JM, Hallak H, Dohert AM, Keiser JA: In vitro pharmacological characterization of PD166285, a new nanomolar potent and broadly active protein tyrosine kinase inhibitor. J Pharm Exp Thera 283(3): 1433-44, 1997
11. Connolly CJ, Hamby JM, Schroeder MC, Barvian M, Lu GH, Panek RL, Amar A, Shen C, Kraker AJ, Fry DW, Klohs WD, Doherty AM: Discovery and structure-activity studies of a novel series of pyrido[2,3-D]pyrimidine tyrosine kinase inhibitors. Bioorg Med Chem Letters 7(18): 2415-20, 1997
12. Klohs WD, Steinkamph R, Driscoll D, Klutchko SR, Hamby, J, Lu GH, Vincent P, Roberts B, Elliott WL: Characterization of PDGF tyrosine kinase inhibitors in in vitro and in vivo tumors. Proc Amer Ass Can Res 38: 632, 1997
13. Hamby JM, Connolly CJ, Schroeder M, Winters R, Showalter H, Panek RL, Major T, Olsewski B, Ryan M, Dahring TK, Lu G, Keiser JA, Amar A, Shen C, Kraker AJ, Slintak V, Nelson JM, Fry DW, Bradford L, Hallak H, Doherty A M: Structure-activity relationships for a novel series of pyrido[2,3-D]pyrimidine tyrosine kinase inhibitors. J Med Chem 40(15): 2296-303, 1997
14. Mohammad M, Froum S, Hamby JM, Schroeder MC, Panek RL, Lu GH, Eliseenkova AV, Green D, Schlessinger J, Hubbard SR: Crystal structure of an angiogenesis inhibitor bound to the FGF receptor tyrosine kinase domain. EMBO J. 17(20): 5896-904, 1998
15. Weishaupt KR, Gomer CJ, Dougherty TJ: Identification of singlet oxygen as the cytotoxic agent in the photoactivation of a murine tumor. Cancer Res 36: 2322-29, 1976
16. Kessel D: Sites of photosensitization by derivatives of hematoporphrin derivative. Photochem Photobiol 44: 489-93, 1986
17. Gibson SL, Cohen HJ, Hilf R: Evidence against the production of superoxide by photoirradiation of hematoporphyrin. Photochem Photobiol 40: 441-48, 1984
18. Star WM, Marijnissen HP, van den Berg-Blok AE, Versteeg JA, Franken KA, Reinhold HS: Destruction of rat mammary tumor and normal tissue microcirculation by hematoporphyrin derivative photoradiation observed in vivo in sandwich observation chambers. Cancer Res 46(5): 2532-40, 1986
19. Reed MW, Schuschke DA, Ackermann DM, Harty JI, Wieman TJ, Miller FN: The response of the rat urinary bladder microcirculation to photodynamic therapy. J Urology 142(3): 865-68, 1989
20. Henderson BW, Dougherty TJ, Malone PB: Studies on the mechanism of tumor destruction by photodynamic therapy. In: D.R. Doiron and C.J. Gomer editors. Porphyrin localization and treatment of tumors. New York, Alan R. Liss, p. 601-12, 1984
21. Beck TM, Hart NE, Woodard DA, Smith CE: Local or regionally recurrent carcinoma of the breast: results of therapy in 121 patients. J Clin Oncol 1(6): 400-5, 1983
22. Sperduto PW, DeLaney TF, Thomas G, Smith P, Dachowski LJ, Russo A, Bonner R, Glatstein E: Photodynamic therapy for chest wall recurrence in breast cancer. Int J Rad One Bio Phy 21(2): 441-6, 1991
23. Wilson CA, Saloupis P, Hatchell DL: Treatment of experimental preretinal neovascularization using photodynamic thrombosis. Invest. Ophthal & Vis Sci 32(9): 2530-5, 1991
24. Miller JW, Stinson WG, Gregory WA, el-Koumy HA, Puliafito CA: Phthalocyanine photodynamic therapy of experimental iris neovascularization. Ophthalmology 98(11): 1711-9, 1991
25. Leonessa F, Green D, Licht T, Wright A, Wingate-Legette K, Lippman J, Gottesman MM, Clarke R: MDA435/LCC6 and MDA/LCC6MDR1: ascites models of human breast cancer. Brit J Cancer 73: 154-61, 1996
26. Slovak M L, Ho JP, Bhardwaj G, Kurz EU, Deeley RG, Cole SP: Localization of a novel multidrug resistance-associated gene in the HT1080/DR4 and H69AR human tumor cell lines, Cancer Res 53(14): 3221-5, 1993
27. Fry DW, Kraker AJ, Connors RC, Elliott WL, Nelson JM, Showalter HD, Leopold WR: Strategies for the discovery of novel tyrosine kinase inhibitors with anticancer activity. Anti-Cancer Drug Design 9(4): 331-51, 1994
28. Martiny-Baron G, Kazanietz mg, Mischak H, Blumberg PM, Kochs G, Hug H, et al.: Selective inhibition of protein kinase C isoenzymes by the indolocarbazole Go 6976. J Biol Chem 268: 9194-7, 1993
29. Skehan P, Storeng R, Scudiero D, Monks A, McMahon J, Vistica D, Warren JT, Bokesch H, Kenney S, Boyd MR: New Colorimetric Cytotoxicity Assay for Anticancer-Drug Screening. J Natl Can Inst 82(13): 1107-12, 1990
30. Holford NH, Scheiner LB: Understanding the dose-effect relationship: Clinical applications of pharmacokinetic-pharmacodynamic models. J Clin Pharmocokin 6(6): 429-53, 1981
31. Nash JC: Compact Numerical Method for Computers: Linear Algebra and Function Minimisation, New York: John Wiley & Sons, 1979
32. Morales DE, McGowan KA, Grant DS, Maheshwari S, Bhartiya D, Cid MC, Kleinman HK, Schnaper HW: Estrogen promotes angiogenic activity in human umbilical vein endothelial cells in vitro and in a murine model. Circulation 9(3): 755-63, 1995
33. Danesi R, Del Bianchi S, Soldani P, Campagni A, La Rocca RV, Myers CE, Paparelli A, Del Tacca M: Suramin inhibits bFGF-induced endothelial cells proliferation and angiogenesis in the chick chorioallantoic membrane. Brit J Cancer 68: 932-8, 1993
34. Kibbey MC, Grant DS, Kleinman HK: Role of the SIK-VAV site of laminin in promotion of angiogenesis and tumor growth: an in vivo matrigel model. J Natl Can Inst 84(21): 16633-8, 1992
35. Sharma A, Pizzolanti G, Oh L, Dougherty TJ, Bernacki RJ: Combination of photodynamic therapy and antiangiogenic therapy for the treatment of human breast cancer in nude athymic mice. Proc Amer Assoc Cancer Res 37: A1980, 1996
36. Henderson BW, Bellnier DA, Greco WR, Sharma A, Pandey RK, Vaughan LA, Weishaupt KR, Dougherty TJ: An in vivo quantitative structure-activity relationship for a congeneric series of pyropheophorbide derivatives as photosensitizers for photodynamic therapy. Cancer Res 57(18): 4000-7, 1997
37. Nicosia RF, Ottinetti A: Modulation of microvascular growth and morphogenesis by reconstituted basement membrane gel in three-dimensional cultures of rat aorta: a comparative study of angiogenesis in matrigel, collagen, fibrin, and plasma clot. In Vitro Cell Dev Bio 26(2): 119-28, 1990
38. Weidner N, Folkman J: Tumoral vascularity as a prognostic factor in cancer. Important Advances in Oncology 167-90, 1996
39. Fidler IJ, Ellis LM. The implications of angiogenesis for the biology and therapy of cancer metastasis. Cell 79(2): 185-88, 1994
40. Shalaby F, Rossant J, Yamaguchi TP, Gertsenstein M, Wu XF, Breitman ML, Schuh AC: Failure of blood-island formation and vasculogenesis in Flk-1-deficient mice. Nature (London) 376: 62-66, 1995
41. Fong G, Rossant J, Gertsenstein M, Breitman ML: Role of the flt-1 receptor tyrosine kinase in regulating the assembly of vascular endothelium. Nature (London) 376: 66-70, 1995
42. Soriano P: Abnormal kidney development and hematological disorders in PDGF β-receptor mutant mice. Genes & Dev 8: 1888-96, 1994
43. Schatteman GC, Motley ST, Effmann EL, Bowen-Pope DF: Platelet-derived growth factor receptor alpha subunit deleted patch mouse exhibits severe cardiovascular dysmorphogenesis. Teratology 51: 351-66, 1995
44. Yamaguchi TP, Harpal K, Henkemeyer M, Rossant J: Fgfr-1 is required for embryonic growth and mesodermal patterning during mouse gastrulation. Genes & Dev 8(24): 3032-44, 1994
45. Brunton VG, Kelland LR, Lear MJ, Montgomery GJ, Robertson JH, Robinson DJ, Queen J, Workman P: Synthesis and biological evaluation of a series of tyrphostins containing nitrothiophene moieties as possible epidermal growth factor receptor tyrosine kinase inhibitors. Anti-Cancer Drug Design 11 (4): 265-95, 1996
46. Gazit A, Osherov N, Gilon C, Levitzki A: Tyrphostin.6. dimeric benzylidenemalononitrile tyrophostins-potent inhibitors of EGF receptor tyrosine kinase in vitro. J Med Chem 39(25): 4905-11, 1996
47. Sawutz DG, Bode DC, Briggs GM, Reid JR, Canniff P, Caldwell L, Faltynek CR, Miller D, Dunn JA, de Garavilla L, Guiles JW, Weigelt C, Michne W, Treasurywala AM, Silver PJ: In vitro characterization of a novel series of platelet-derived growth factor receptor tyrosine kinase inhibitors. Biochem Pharm 51(12): 1631-8, 1996
48. Kohn EC, Liotta LA: Molecular insights into cancer invasion: strategies for prevention and intervention. Cancer Res 55: 1856-62, 1995
49. Eckhardt SG, Pluda JM: Development of angiogenesis inhibitors for cancer therapy. Inv New Drugs 15: 1-3, 1997
50. Voest EE: Inhibitors of angiogenesis in a clinical perspective, Anti-Cancer Drugs 7: 723-7, 1996
51. Sharma A, Bernacki RJ: Ovarian cancer patients with CA-125 but no symptoms - Should antiangiogenic treatments be considered? Oncology Res 9(2): 53-4, 1997
52. Dimitroff CJ, Sharma A, Bernacki RJ: Cancer metastasis: a search for therapeutic inhibition. Cancer Invest 16(4): 279-90, 1998
53. Boehm T, Folkman J, Browder T, O'Reilly MS: Antiangiogenic therapy of experimental cancer does not induce acquired drug resistance, Nature 390(27): 404-7, 1997
54. Chang SC, Bown SG: Photodynamic therapy - applications in bladder cancer and other malignancies. J Form Med Assoc 96(11): 853-63, 1997
55. Schuh M, Nseyo UO, Potter WR, Dao T, Dougherty TJ: Photodynamic therapy for palliation of locally recurrent breast carcinoma. J Clin One 5(11): 1766-70, 1987
56. Khan SA, Dougherty TJ, Mang TS: An evaluation of photodynamic therapy in the management of cutaneous metastasis of breast cancer. Eur J Cancer 29A: 1686-90, 1993
57. Wilson BD, Mang TS, Stoll H, Jones C, Cooper M, Dougherty TJ: Photodynamic therapy for the treatment of basal cell carcinoma. Arch Derm 128(12): 1597-601, 1992
58. Narayan S, Sivak MV. Jr: Palliation of esophageal carcinoma. Laser and photodynamic therapy. Chest Surg Clin North Amer 4(2): 347-67, 1994
59. Nseyo UO, Dougherty TJ, Boyle DG, Potter WR, Wolf R, Huben R, Pontes JE: Whole bladder photodynamic therapy for transitional cell carcinoma of the bladder, Urology 26(3): 274-80, 1985
60. Dougherty TJ: Photodynamic therapy: status and potential. Oncology 3(7): 67-73, 1989
61. Dougherty TJ: Photodynamic therapy for early stage lung cancer. Preferable to resection? Chest 102(5): 1319-22, 1992